文献速递泌尿生殖与妇科肿瘤放疗

低剂量率近距离放疗后低危与中危前列腺癌的「治愈」定义:Phoenix定义还是手术定义

Definitions of "Cure" After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
PubMed 文献 · Adv Radiat Oncol · 2022-10-21

本研究在427例接受125I低剂量率近距离放疗(160 Gy)的低危(62.8%)与中危(37.2%)前列腺癌患者中,比较Phoenix定义与手术定义(治疗后前列腺特异性抗原≤0.2 ng/mL)在4年时判定治愈的效果。两种定义的特异性均为100%,Phoenix定义敏感度97.4%、手术定义96.3%,阳性预测值均为100%,阴性预测值分别为29%与7.7%,准确率分别为94.8%与96.3%。作者认为两种定义均可用于可靠评估治愈。

要点

  • 427例低中危前列腺癌接受125I低剂量率近距离放疗160 Gy后4年,Phoenix定义可评估427例、手术定义可评估327例。
  • 两种定义特异性均100%、阳性预测值均100%,Phoenix定义敏感度97.4%、手术定义96.3%。
  • Phoenix定义阴性预测值29%、手术定义7.7%,准确率分别为94.8%与96.3%。

核心结论

  • 两种定义均可用于可靠评估低危与中危前列腺癌患者低剂量率近距离放疗后的治愈。
  • 作者认为4年起达到治愈的患者可采用不那么密集的随访方案,而未达到治愈者应延长监测时间。

研究设计与样本

  • 研究纳入427例可评估的低危(62.8%)与中危(37.2%)前列腺癌男性,接受125I低剂量率近距离放疗(160 Gy)。
  • 治愈在4年时分别按Phoenix定义(未出现生化复发)或手术定义(治疗后前列腺特异性抗原≤0.2 ng/mL)判定。
  • 采用Kaplan-Meier法计算5年与10年的生化复发无生存、无转移生存与癌症特异性生存。
  • 采用标准诊断试验评价方法比较两种定义对后续转移失败或癌症特异性死亡的判定效能。

主要发现

  • 48个月时,Phoenix定义可评估427例、手术定义可评估327例。
  • Phoenix定义治愈队列5年与10年生化复发无生存分别为97.4%与89%,无转移生存分别为99.5%与96.3%。
  • 手术定义治愈队列5年与10年生化复发无生存分别为98.2%与92.7%,无转移生存分别为100%与99.4%。
  • 两种定义判定治愈的特异性均为100%,敏感度Phoenix定义97.4%、手术定义96.3%。
  • 两种定义阳性预测值均为100%,阴性预测值Phoenix定义29%、手术定义7.7%,准确率分别为94.8%与96.3%。

关键数值与推荐

  • Phoenix定义:4年时未按Phoenix定义出现生化复发。
  • 手术定义:4年时治疗后前列腺特异性抗原≤0.2 ng/mL。
  • 低剂量率近距离放疗剂量为160 Gy。

临床怎么用

  • 作者认为两种定义均可用于可靠评估低危与中危前列腺癌患者低剂量率近距离放疗后的治愈。
  • 作者认为4年起达到治愈的患者可采用不那么密集的随访方案。
  • 作者认为4年时未达到治愈的患者应延长监测时间。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to compare a surgical with a Phoenix-derived definition of cure at 4 years after treatment by 125J low-dose-rate brachytherapy (LDR-BT) in patients with low- and intermediate-risk prostate cancer. METHODS AND MATERIALS: A total of 427 evaluable men with low-risk (62.8%) and intermediate-risk (37.2%) prostate cancer were treated with LDR-BT (160 Gy). Cure was defined at 4 years either as not having experienced a biochemical recurrence by the Phoenix definition, or by a surgical definition, using a posttreatment prostate-specific antigen of ≤0.2 ng/mL. Biochemical recurrence-free survival (BRFS), metastasis-free survival (MFS), and cancer-specific survival were calculated at 5 and 10 years using the Kaplan-Meier method. Standard diagnostic test evaluations were used to compare both definitions with regard to later metastatic failure or cancer-specific death. RESULTS: At 48 months, 427 patients were evaluable with a Phoenix-defined and 327 with a surgical-defined cure. At 5 and 10 years BRFS was 97.4% and 89% and MFS was 99.5% and 96.3% in the Phoenix-defined cure cohort, and BRFS was 98.2% and 92.7% and MFS was 100% and 99.4% in the surgical-defined cure cohort. Specificity for cure was 100% for both definitions. Sensitivity was 97.4% for the Phoenix and 96.3% for the surgical definition. The positive predictive value was 100% for both, whereas the negative predictive value was 29% for the Phoenix and 7.7% for the surgical definition. Accuracies of a correct prediction of cure were 94.8% and 96.3% for the Phoenix and the surgical definition, respectively. CONCLUSIONS: Both definitions are useful for a reliable assessment of cure after LDR-BT in patients with low-risk and intermediate-risk prostate cancer. Cured patients might follow a less stringent follow-up schedule from 4 years onward, whereas patients not achieving cure at 4 years should be monitored for an extended time.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Boehle A, Zywietz D, Robrahn-Nitschke I, et al. Definitions of "Cure" After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical? Adv Radiat Oncol. 2022. PMID: 36845613. doi:10.1016/j.adro.2022.101112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。